Glenmark Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Progesterone Vaginal Inserts, 100 mg, marking a significant addition to its generics portfolio in the United States. The approved product has been deemed bioequivalent and therapeutically equivalent to the reference listed drug, Endometrin® Vaginal Inserts, 100 mg.
The product will be marketed in the US through Glenmark Pharmaceuticals Inc, USA, expanding the company’s offerings in the women’s healthcare segment. Progesterone-based therapies are widely used in fertility treatments and reproductive health management, making this approval an important step in addressing patient needs in this therapeutic area.
Market data indicates that the reference product recorded annual sales of approximately $59.2 million for the 12-month period ending February 2026, highlighting the commercial opportunity in this segment. The approval positions Glenmark to participate in this market while offering an alternative that meets regulatory standards for safety, efficacy, and quality.
Company leadership noted that the approval aligns with Glenmark’s strategy to broaden access to affordable medicines while strengthening its presence in key global markets. The addition of Progesterone Vaginal Inserts to its portfolio reflects a continued focus on expanding treatment options in specialized therapeutic categories.
Glenmark operates as a research-driven pharmaceutical company with a global footprint spanning more than 80 countries. Its business includes branded formulations, generics, and specialty products, supported by a network of manufacturing facilities and research and development centers across multiple regions.
The company has consistently invested in innovation and regulatory capabilities to support product development and approvals in highly regulated markets such as the United States. This latest approval adds momentum to its efforts to build a diversified and competitive product pipeline.
With a presence across therapeutic areas including respiratory, dermatology, and oncology, Glenmark continues to pursue growth opportunities that combine innovation with accessibility. The approval of Progesterone Vaginal Inserts further strengthens its commitment to delivering quality healthcare solutions and expanding treatment access for patients globally.
